ELOCTA

DRUG3 trials

Sponsors

Swedish Orphan Biovitrum, Bayer

Conditions

Haemophilia AHaemophilia BHemophilia A

Phase 1

BAY94-9027 PK Study Comparing to Another Long Acting Product

CompletedNCT03364998

BayerHemophilia A

Start: 2017-11-30End: 2018-09-28Updated: 2019-09-09

Unknown Phase

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

CompletedNCT03055611

Swedish Orphan BiovitrumHaemophilia A, Haemophilia B

Start: 2017-05-09End: 2022-04-19Updated: 2024-10-02

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Active, not recruitingNCT04293523

Swedish Orphan BiovitrumHemophilia A

Start: 2020-03-30End: 2026-07-01Updated: 2026-03-19

Related Papers

Post-Hoc Analyses of A-SURE and PREVENT Confirm the Effectiveness of rFVIIIFc Prophylaxis Across All Ages, BMIs, Severities and Inhibitor Histories

TH Open2026-06-16

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

2024-08-202 citations

Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.

2024-06-213 citations

Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Blood2020-11-04

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

Annals of Hematology2019-06-2429 citations

Baseline Data from a 24-month Prospective, Non-interventional, Multicentre Study in Germany to Evaluate the Real-world Usage and Effectiveness of rFVIIIFc and rFIXFc in Patients with Haemophilia A or B (PREVENT)

Hämostaseologie2019-02-01